Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: A review

Blood Reviews

Volumn 17, Issue SUPPL. 1, 2003, Pages

  Grounds, Mike ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Haemostasis; Recombinant FVIIa; Surgery; Trauma

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GUNSHOT INJURY; HEMOPHILIA; HEMOSTASIS; HUMAN; PEROPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; THROMBOSIS;

EID: 0242267415     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(03)90002-6     Document Type: Conference Paper

References (49)

1. Kenet G. rFVIIa for profuse bleeding in surgical patients. Bloodline Reviews 2001; 1: 12-13.
2. Flati G, Andren-Sandberg A, La Pinta M, Porowska B, Carboni M. Potentially fatal bleeding in acute pancreatitis: pathophysiology, prevention, and treatment. Pancreas 2003; 26: 8-14.
3. Dunn CJ, Goa KL. Fibrin sealant: a review of its use in surgery and endoscopy. Drugs 1999; 58: 863-886.
4. Carless PA, Anthony DM, Henry DA. Systematic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion. Br J Surg 2002; 89: 695-703.
5. Copeland GP, Jones D, Walters M. POSSUM: a scoring system for surgical audit. Br J Surg 1991; 78: 355-360.
6. Boyd CR, Tolson MA, Copes WS. Evaluating trauma care: the TRISS method. Trauma Score and the Injury Severity Score. J Trauma 1987; 27: 370-378.
7. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001a; 51: 431-439.
8. Lockey DJ. Prehospital trauma management. Resuscitation 2001; 48: 5-15.
9. Trunkey DD. Trauma. Sci Am 1983; 249: 28-35.
10. Lynn M. Use of recombinant factor VIIa in the post-injury period: a trauma surgeon's perspective. Bloodline Reviews 2001; 1: 7-8.
11. Gofrit ON, Leibovici D, Shapira SC, Shemer J, Stein M, Michaelson M. The trimodal death distribution of trauma victims: military experience from the Lebanon War. Mil Med 1997; 162: 24-26.
12. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: a reassessment. J Trauma 1995; 38: 185-193.
13. Kobayashi K. Damage control surgery - a historical view. Nippon Geka Gakkai Zasshi 2002; 103: 500-502.
14. Williamson LM, Lowe S, Love EM, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ 1999; 319: 16-19.
15. Ferrara A, MacArthur JD, Wright HK, Modlin IM, McMillen MA. Hypothermia and acidosis worsen coagulopathy in the patient requiring massive transfusion. Am J Surg 1990; 160: 515-518.
16. Hedner U. Recombinant factor VIIa (NovoSeven®) as a haemostatic agent. Bloodline Reviews 2001; 1: 3-4.
17. Allen GA, Hoffman M, Roberts HR, Monroe DM 3rd. Recombinant activated factor VII; is mechanism of action and role in the control of haemorrhage. Can J Anaesth 2002; 49: S7-S14.
18. Murkin JM. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice. Can J Anaesth 2002; 49: S21-S26.
19. Kenet G, Walden R, Eldad A, Martinowitz U et al. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
20. Martinowitz U, Holcomb JB, Pusateri AE, Macaitis JM, Hedner U, Hess JR. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001b; 50: 721-729.
21. O'Neill PA, Bluth M, Gloster ES, et al. Successful use of recombinant activated factor VII for trauma-associated haemorrhage in a patient without preexisting coagulopathy. J Trauma 2002; 52: 400-405.
22. Friederich PW et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomized trial. Lancet 2003; 362: 201-205.
23. Porte RJ. The risk of bleeding during liver surgery and liver transplantation and effect on outcome. Bloodline Reviews 2001; 1: 14-15.
24. Shami VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG. Recombinant activated factor VII for coagulopathy for fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003; 9: 138-143.
25. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113: 1930-1937.
26. Hendriks HG, Meijer K, de Wolf JT, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001a; 71: 402-405.
27. Ejlersen E, Melsen T, Ingerslev J, Andreasen RB, Vilstrup H. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 2001; 36: 1081-1085.
28. Lodge P, Jonas S, Jaeck D, Fridberg MJ. Recombinant factor VIIa (NovoSeven®) in partial hepatectomy: a randomized, placebo-controlled, double-blind clinical trial. Presented at the American Association for the Study of Liver Diseases Annual Meeting, Boston, Nov 2002. Abstract 177.
29. Lisman T, Leebeek FW, Meijer K, Van Der Meer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa improves clot formation but not fibrinolytic potential in patients with cirrhosis and during liver transplantation. Hepatology 2002; 35: 616-621.
30. Meijer K, Hendriks HG, de Wolf JT, et al. Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. Blood Coagul Fibrinolysis 2003; 14: 169-174.
31. Hendriks HGD, Meijer K, de Wolf JT, et al. Effects of recombinant activated factor VIIa on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 2002; 13: 309-313.
32. Aggarwal A, Catlett J, Alcorn K. Use of recombinant activated factor VII (rFVIIa) in the management of intractable bleeding in surgical and trauma patients. Presented at the American Society of Hematology 43rd Annual Meeting, Orlando, Dec 2001. Abstract 3883.
33. Svartholm E, Annerhagen V, Lanne T. Treatment of bleeding in severe necrotizing pancreatitis with recombinant factor VIIa. Anesthesiology 2002; 96: 1528.
34. Ng HJ, Koh LP, Lee LH. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 2003; 82: 257-258.
35. Hendriks HG, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff MJ, van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001b; 93: 287-289.
36. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb 2002; 32 (Suppl 1): 41-46.
37. Zietkiewicz M, Garlicki M, Domagala J, et al. Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device. J Thorac Cardiovasc Surg 2002; 123: 384-385.
38. Potapov EV, Pasic M, Bauer M, Hetzer R. Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device. Ann Thorac Surg 2002; 74: 2182-2183.
39. Kastrup M, von Heymann C, Hotz H, et al. Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta. Ann Thorac Surg 2002; 74: 910-912.
40. Von Heymann C, Hotz H, Konertz W, Kox WJ, Spies C, Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2002; 16: 615-616.
41. Dietrich W, Spannagl M. Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anesth Analg 2002; 94: 1369-1371.
42. Roberts HR. Recombinant factor VIIa (NovoSeven®) and the safety of treatment Semin Hematol 201; 38 (Suppl 2): 48-50.
43. Hoffman M, Monroe DM 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl 1); S61-S65.
44. Erhardtsen E. Ongoing NovoSeven®trials. Intensive Care Med 2002; 28 (Suppl 2): S248-S256.
45. Mikhail J. The trauma triad of death: hypothermia, acidosis, and coagulopathy. AACN Clin Issues 1999; 10: 85-94.
46. Lynn M, Jeroukhimov I, Klein Y, Martinowitz U. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med 2002; 28 (Suppl 2): S241-S247.
47. Peng RY, Bongard FS. Hypothermia in trauma patients. J Am Coll Surg 1999; 188: 685-696.
48. Szaflarski N, Hanson CW 3rd. Metabolic acidosis. AACN Clin Issues 1997; 8: 481-496.
49. Krishna G, Sleigh JW, Rahman H. Physiological predictors of death in exsanguinating trauma patients undergoing conventional trauma surgery. Aust NZJ Surg 1998; 68: 826-829.